|
Steatohepatitis
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, acylated and desacyl ghrelin inhibited steatosis and inflammation of palmitate-treated hepatocytes in parallel to an upregulation of OXPHOS complexes II, III, and V, and a downregulation of ER stress transducers IRE1α, PERK, ATF6, their downstream effectors, ATF4 and CHOP, as well as chaperone GRP78.
|
31324878 |
2020 |
|
Steatohepatitis
|
0.340 |
Biomarker
|
disease |
BEFREE |
G0S2 is regulated by the PERK-eIF2α-ATF4 branch of the UPR and mediates ER stress-induced hepatic steatosis.
|
31271806 |
2019 |
|
Steatohepatitis
|
0.340 |
Biomarker
|
disease |
BEFREE |
Moreover, AgRP-ATF4 KO mice were resistant to high-fat diet-induced obesity, insulin resistance, and liver steatosis and maintained at a higher body temperature under cold stress.
|
27993927 |
2017 |
|
Steatohepatitis
|
0.340 |
Biomarker
|
disease |
BEFREE |
We observed early-onset hyperlipidaemia and liver steatosis in ATF4 transgenic zebrafish (ATs) without doxycycline treatment (ATs - Dox).
|
29180630 |
2017 |
|
Fatty Liver
|
0.330 |
Biomarker
|
disease |
BEFREE |
G0S2 is regulated by the PERK-eIF2α-ATF4 branch of the UPR and mediates ER stress-induced hepatic steatosis.
|
31271806 |
2019 |
|
Fatty Liver
|
0.330 |
Biomarker
|
disease |
BEFREE |
Moreover, AgRP-ATF4 KO mice were resistant to high-fat diet-induced obesity, insulin resistance, and liver steatosis and maintained at a higher body temperature under cold stress.
|
27993927 |
2017 |
|
Fatty Liver
|
0.330 |
Biomarker
|
disease |
BEFREE |
We observed early-onset hyperlipidaemia and liver steatosis in ATF4 transgenic zebrafish (ATs) without doxycycline treatment (ATs - Dox).
|
29180630 |
2017 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Specifically, our cell biology and gene expression studies have revealed that DISC1 Leu607Phe variation, which changes DISC1 interaction with activating transcription factor 4 (ATF4), modifies gene expression patterns upon T. gondii infection.
|
30127472 |
2020 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
These findings support that ATF4 gene may be involved in susceptibility to schizophrenia with sex-dependent effect in the Chinese Han population and suggest that further functional assays are needed to verify their relevance to the pathogenesis of schizophrenia.
|
18163433 |
2008 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
In this study, we tested genetic association of ATF4 and ATF5 genes with bipolar disorder by a case-control study in Japanese population (438 patients and 532 controls) and transmission disequilibrium test in 237 trio samples from NIMH Genetics Initiative Pedigrees.
|
17346882 |
2007 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since pharmacological activation of ATF4 exerts potent anti-tumor effects, modulators of ATF4 activation may have potential in cancer therapy.
|
31461933 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that targeting the TGF-β<sub>1</sub>-mTORC1-ATF4 axis may represent a novel therapeutic strategy for interfering with myofibroblast function in fibrosis and potentially in other conditions, including cancer.
|
31113850 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Rationale</b>: Activating transcription factor 4 (ATF4) is a central regulator of the cellular stress response and reduces tumor burden by controlling the expression of target genes implicated in the induction of apoptosis.
|
31534554 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that the ATF4/p-eIF2α pathway is activated in response to Sunitinib in primary tumor initiating progenitor cell cultures (BTICs).
|
30719230 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we identified ATF4 target genes (<i>LZTFL1, MKNK2</i>, and <i>SIAH1</i> with known tumor suppressor function) that were synergistically upregulated with the combination of TKI and ERAD inhibitor.
|
30552230 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, endoplasmic reticulum (ER) stress in tumor samples or cells was markedly induced by CA treatment through promoting the expression of associated signals such as Parkin, protein kinase RNA-like ER kinase (PERK), activating transcription factors 4 (ATF4) and ATF6.
|
31545234 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Since pharmacological activation of ATF4 exerts potent anti-tumor effects, modulators of ATF4 activation may have potential in cancer therapy.
|
31461933 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that targeting the TGF-β<sub>1</sub>-mTORC1-ATF4 axis may represent a novel therapeutic strategy for interfering with myofibroblast function in fibrosis and potentially in other conditions, including cancer.
|
31113850 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ICD inducers including anthracyclines and agents that provoke tetraploidization were highly efficient in enhancing the phosphorylation of eIF2α, yet failed to stimulate other signs of ER stress including the transcriptional activation of activating transcription factor 4 (ATF4), the alternative splicing of X-box binding protein 1 (XBP1s) mRNA and the proteolytic cleavage of activating transcription factor 6 (ATF6) both in vitro and in cancers established in mice.
|
29358668 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review highlights the recent literature on ferroptotic and apoptotic agent interactions through the ER stress-mediated PERK-eIF2α-ATF4-CHOP-PUMA pathway and implicates combined treatment to effectively enhance tumoricidal efficacy as a novel therapeutic strategy for cancer.<i></i>.
|
29592897 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We defined an eight-gene signature with prognostic potential, altered in 45% of 2,509 patients with breast cancer.<b>Conclusions:</b> ATF4 may represent a valuable prognostic biomarker and therapeutic target in patients with TNBC, and we identified a cell signaling pathway-based gene signature that may contribute to the development of combinatorial targeted therapies for breast cancer.<i>Clin Cancer Res; 24(22); 5697-709.©2018 AACR</i>.
|
30012564 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Relationship between TGFβ and ATF4, their effects on aggressiveness (tumor proliferation, metastasis, and stemness), and the underlying pathways were analyzed in three TNBC cell lines and <i>in vivo</i> using patient-derived xenografts (PDX).<b>Results:</b><i>ATF4</i> overexpression correlated with TNBC patient survival decrease and a SMAD-dependent crosstalk between ATF4 and TGFβ was identified.
|
30012564 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, indicators of UPR, PERK, p-eIF2α and GRP78, increased (<i>p</i> < 0.05), whereas ATF4 was strongly decreased (<i>p</i> < 0.01) in the liver of tumor-bearing mice while sACVR2B-Fc had no effect.
|
30713500 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The eIF2<i>α</i>/ATF4 pathway is responsible for the integrated stress response (ISR) of unfolded protein response (UPR) which can affect immune cell function in tumor microenvironment.
|
30305853 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
This review highlights the recent literature on ferroptotic and apoptotic agent interactions through the ER stress-mediated PERK-eIF2α-ATF4-CHOP-PUMA pathway and implicates combined treatment to effectively enhance tumoricidal efficacy as a novel therapeutic strategy for cancer.<i></i>.
|
29592897 |
2018 |